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Circulating platelet-derived microparticles with procoagulant ac- Uremic patients seem to have two opposite aspects in
tivity may be a potential cause of thrombosis in uremic patients. hemostatic status, which are bleeding and thrombotic
Background. Clinical experience indicates that bleeding and tendencies. A number of experimental studies have re-thrombotic tendencies co-exist in uremic patients. Numerous
vealed platelet functional defects in uremia, such as di-studies have shown that platelet functional defects contribute
minished adherence to vascular subendothelium [1, 2],to the bleeding tendency in uremic patients. In contrast, there
are no solid studies clarifying the pathogenesis of the prothrom- decreased expressions of platelet membrane glycopro-
botic state in uremic patients. Platelet-derived microparticles tein GIb [3] and dysfunction of glycoprotein GIIb/IIIa
(PMPs), which are small vesicles with procoagulant activity re-
[4]. The bleeding tendency in such patients, therefore,leased from activated platelets, are thought to be involved in
may be due to the functional impairments of plateletsclinical thrombogenesis. This study addressed the question of
why uremic patients are thrombophilic even though they have a in normal hemostasis [5, 6]. On the other hand, clinical
bleeding tendency, focusing on the clinical significance of PMPs. statistics suggest that uremic patients have a high inci-
Methods. The subjects were pre-dialyzed patients, patients dence of thrombotic events [7, 8]. Moreover, a throm-under hemodialysis (HD) or continuous ambulatory peritoneal
botic tendency, caused by factors such as platelet hyper-dialysis (CAPD) therapy, and age-matched healthy controls.
aggregability and hypercoagulability, has been describedAnalyses of PMPs were performed using a flow cytometer. An-
nexin V was used to probe procoagulant activity of PMPs. The in dialysis patients [9–12]. This evidence emphasizes that
impacts of the HD procedure, arteriovenous (AV) fistula, and acute arterial occlusion can be facilitated under a uremic
recombinant human erythropoietin (rHuEPO) treatment on
situation. However, to our knowledge there are no stud-the release of PMPs were additionally assessed.
ies giving a definite answer to the question of why uremicResults. Major results are: (1) PMP counts were significantly
greater in each uremic group than in controls. The PMP counts patients often show a thrombophilic tendency despite
were not different among three types of uremic groups; (2) their vulnerability in physiological hemostatic functions.
PMP counts were significantly higher in uremic patients with Platelets release small particles called platelet-derivedthrombotic events than in those without thrombotic events;
microparticles (PMPs) after they are activated by someand (3) the HD procedure and existence of AV fistula did not
chemical stimuli or high shear stress [13–19]. The majoraffect PMP counts, but rHuEPO treatment possibly enhanced
the PMP release in these patients. functional significance of PMPs is associated with its pro-
Conclusions. Elevated PMP counts may trigger thrombosis coagulant activity. PMPs are enriched with membrane
in uremic patients. The primary cause of PMP elevation in
receptors for coagulation factor Va, and provide a cata-uremia was not clarified in this study.
lytic surface for the prothrombinase reaction, contribut-
ing to the acceleration of thrombin generation [13, 14].
Thus, PMPs may play a pivotal role in acute arterial
occlusion in atherosclerotic small arteries or arterioles
where pathological levels of fluid shear stress may occurKey words: thrombosis, flow cytometric analysis, procoagulant activity,
annexin V, bleeding tendency, platelet function, acute arterial occlusion. [15–19]. Elevated counts of circulating PMPs have been
reported in association with thrombotic disorders, suchReceived for publication October 10, 2001
as cerebrovascular accidents [20], unstable angina [21],and in revised form June 10, 2002
Accepted for publication June 12, 2002 and acute myocardial infarction [22]. In addition, PMPs
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activate such cells and transport their chemical mediators Blood collection, preparation of washed platelets,
and cell labelingto those cells, potentially leading to the development of
thrombosis and atherosclerosis [23–26]. We hypothe- Blood samples were obtained before the start of treat-
sized that an enhancement of PMP generation—if it ment at the first HD of the week in the HD patients, or
exists—may participate in thrombogenesis and compen- when patients visited the hospital for their regular medi-
sation for the bleeding tendency in uremia. cal examination in the CAPD or pre-dialyzed patients.
This study used flow cytometry [13, 14, 18] to evaluate Two milliliters of venous blood were placed into a tube
the PMPs in healthy subjects and three types of uremic containing 0.2 mL of an EDTA-ACD solution [ethylene-
diaminetetraacetic acid (EDTA)–2 Na 1.0 g, trisodiumpatients: those who were pre-dialyzed, on hemodialysis
citrate 2.2 g, citric acid 807 mg, dextrose 2.2 g in 100 mL(HD), and on continuous ambulatory peritoneal dialysis
of distilled water] and gently inverted twice. Platelet-(CAPD) therapy. The procoagulant activity of PMPs
rich plasma (PRP) was prepared by centrifugation atwere especially evaluated by annexin V, a placental pro-
180  g for 20 minutes at room temperature. An aliquottein with a high affinity and specificity for aminophos-
(15 L) of the PRP that had been diluted up to 50 Lpholipids, which has been shown to be an appropriate
with 0.1% EDTA-saline was then incubated with 2 Lprobe for detecting such specific activity of PMPs [27].
of FITC-GPIb and PE-annexin V for 30 minutes at roomIn addition, the concomitant influences of the HD proce-
temperature in the dark. Nonspecific FITC-labeled mAbdure, existence of internal arteriovenous (AV) fistula, and
was used for the negative controls.chronic recombinant human erythropoietin (rHuEPO)
therapy on PMP formation were studied. Flow cytometry
Samples were analyzed using a flow cytometer (FACS
Calibur; Becton Dickinson). The light scatter and fluo-METHODS
rescence channels were set at a logarithmic gain. TheReagents and antibodies
gating methods for PMPs are shown in Figure 1. Only
Fluorescein isothiocyanate (FITC)-conjugated mono- cells and particles positive for GPIb were gated to distin-
clonal antibody (mAb) to GPIb, NNKY5-5 [28], was a guish platelets and PMPs from electronic noise as fol-
generous gift from Dr. Shosaku Nomura, Kansai Medical lows: The cells labeled with monoclonal antibody (mAb)
School (Osaka, Japan). Phycoerythrin (PE)-conjugated to FITC-GPIb (R1) were gated on the side scatter (SSC)
annexin V was purchased from Pharmingen (San Diego, dot plot versus fluorescence-1 (FL-1) profile, which was
CA, USA). Isotype-matched mAbs of irrelevant speci- determined by comparing with the dot plot profile of
ficity (FITC-labeled mouse IgG) were purchased from the samples treated with non-labeled mAb to GPIb
Becton Dickenson (San Diego, CA, USA). Calibrated (Fig. 1A). Regions corresponding to PMPs (R3) were
latex beads (SPHERO Fluorescent Particles) were pur- then discriminated from the platelet islet contaminated
chased from Pharmingen. (R2) by reviewing the cells in the gate R1 on SSC dot
plot versus the forward scatter (FSC) dot plot profile
Subjects (Fig. 1B). A known number of fluorescent latex beads
Twenty-nine healthy subjects and 46 HD patients, 23 (30,000) were added to each sample tube before analysis
CAPD patients, and 20 pre-dialyzed uremic patients [30], and the time of analysis was defined by counting a
were studied. Diabetic patients were not included to pre-determined bead number (300 counts). The percent-
age of PMPs positive for PE-annexin V in the cells ofestimate the simple influence of uremia on PMP genera-
the gate R3 was evaluated on histograms (Fig. 1C) con-tion [29]. Patients who had been receiving anti-platelet
structed by the analysis software, CellQuest (Becktondrugs were excluded. The subjects’ profiles are shown
Dickinson). The bar was determined as the specific posi-in Table 1. Each patient population was matched for age
tive region of PE-annexin V. The particles in the R3with the healthy population (mean age, 52.3 5.19 years).
were designated as crude PMPs. The absolute numberA majority of the dialysis patients had been treated with
of PMPs stained by annexin V was calculated by therecombinant human erythropoietin (rHuEPO), which was
following formula:intravenously injected three times a week in the HD
patients, and subcutaneously administered once a week Counts of specific PMPs
in the CAPD and pre-dialyzed patients. The HD patients
 (crude PMP counts in the gate R3)were dialyzed using columns of different types of mem-
brane materials: polysulfone, cellulose-triacetate, or poly-  (percentage of the stained
methylmethacrylate. Heparin, as an anticoagulant agent,
cells in the gate R3)  0.01.was continuously injected at a dose of 600 to 800 units
per hour during HD treatment. These specific PMPs with procoagulant activity were
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Fig. 2. Comparison of PMP counts between three types of uremic
patients (HD, CAPD, and pre-dialyzed uremic patients) and controls.
Each patient population was matched for age with the controls. The
significant differences were obtained between each uremic group and
the controls. The PMP counts were not different among three types of
uremic patients. Statistically significant difference is marked. **P 
0.01 vs. control.
simply designated as “PMPs” in the following description
unless otherwise stated. The study was approved by the
institutional review board of the hospital and was carried
out according to the principles of the Declaration of
Helsinki. Informed consent was obtained from all of the
subjects included in this study.
Statistics
Data were expressed as mean  SD unless otherwise
stated. The differences between mean values were evalu-
ated by the two-tailed Student t test for comparing two
groups and by the analysis of variance (ANOVA) fol-
lowed by Bonferroni-Dunn for comparing more than
three groups. P  0.05 was considered statistically sig-
nificant.
RESULTS
PMP counts in uremic patients
The PMP counts were studied in 89 non-DM uremic
patients and 29 age-matched controls. The PMP counts
were significantly higher in each uremic group (pre-dia-
lyzed, 142.3  49.5; HD, 195.3  103.1; CAPD, 161.0 
47.9) than in the controls (104.9 46.3). The PMP counts
were not different among three types of uremic groups
(Fig. 2). The PMP counts did not correlate with platelet
Fig. 1. (A) Cells stained with monoclonal antibody (mAb) to FITC-
GPIb were gated as R1 on the side scatter (SSC) dot plot versus the
fluorescence-1 (FL-1) profile. R1 was determined by referring to the from the platelet islet shown as R2. (C ) The percentage of PMPs
SSC versus FL-1 profile of the samples treated with non-labeled mAb positive for PE-annexin V in the cells of R3 was evaluated with a
to GPIb. (B) The cells in R1 were reviewed on SSC dot plot versus histogram analysis. The bar was determined as the specific positive
the forward scatter (FSC) dot plot profile. Regions corresponding to region of PE-annexin V by comparison with the histograms of the
platelet-derived microparticles (PMPs; R3) were discriminated by size samples treated with non-labeled Ab to annexin V.
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Fig. 3. Comparison of PMP counts between uremic patients with
thrombotic events and those without such events. Both patients were
Fig. 4. Comparisons of platelet-derived microparticle (PMP) countsmatched for age. PMP counts were significantly higher in the uremic
between recombinant human erythropoietin (EPO) recipients and non-group with thrombotic events than in those who had not experienced
recipients in dialysis patients. The significant differences between thethrombotic events. Statistically significant difference is marked. **P 
recipients and non-recipients were obtained in each subgroup of dialysis0.01 vs. uremic group without thrombotic events.
patients. Statistically significant difference is marked. *P 0.05 vs. non-
recipients.
counts and serum levels of albumin, urea nitrogen, and
creatinine in any uremic group. rHuEPO recipients, as shown in Table 1. No significant
correlation was obtained between the PMP counts and
PMP counts in uremic patients with and rHuEPO dose administered in each dialysis subgroup.
without thrombotic events Regardless of rHuEPO use, the PMP counts were sig-
A clinical link between PMP counts and thrombotic nificantly higher in the EPO non-recipients of HD (N 
events were examined in all uremic subjects. The throm- 30; 148.9 80.5), CAPD (N 10, 138.0 34.3), and pre-
botic events were retrospectively investigated. Overall, dialyzed (N  18; 133.1  42.3) patients than in the
the number of patients who had suffered thrombotic controls. In addition, PMP counts were significantly higher
events for the last five years was 15 out of 89 patients (P  0.0260) even in the uremic patients without throm-
(17.4%; 9 of 46 HD patients, 3 of 23 CAPD patients, botic events receiving no rHuEPO treatment (N  38,
and 3 of 20 pre-dialyzed patients). The PMP counts in 131.6 48.7) than in the controls (N 29, 104.9 46.3).
the patients with thrombotic events (248.5  91.1) were
Influence of HD therapy on PMP generationsignificantly greater than in the patients without such
events (159.5  74.5; Fig. 3). Changes in PMP counts during HD treatment. The time
courses in PMP counts were examined in 14 HD patients
Effects of rHuEPO on the PMP count before and 10 minutes, 30 minutes, and 2, 3, and 4 hours
in dialysis patients after starting the HD treatment. Blood samples were
The PMP counts were compared between the HD collected from the outlet port of the HD circuit tube
patients receiving chronic rHuEPO treatment (recipi- before the dialysis column. The counts of PMP did not
ents; 220.0  106.5, N  30) and those receiving no such significantly change during HD treatment. The data are
treatment (non-recipients; 148.9  80.5, N  16). The shown in Figure 5A.
PMP counts of the EPO recipients were significantly Changes in PMP count before and after dialysis col-
higher than those of the EPO non-recipients (Fig. 4). umns. The changes of PMP counts before and after dial-
Both groups were matched for age (59.2 12.8 vs. 55.4 ysis columns were specially examined to better under-
11.4 years old). The mean dose of rHuEPO used was stand the influence of blood contact with membrane
2380 921 units a week. Moreover, the significant differ- materials on PMP counts at two hours after the start of
ence in the PMP counts between the EPO recipients HD. No significant changes in PMP counts were ob-
(178.7  50.3, N  13) and non-recipients (138.0  34.3, served before and after the columns (before, 188.7 
N  10) was found in the subgroup of CAPD (Fig. 4). 22.3; after, 193.1  41.5; Fig. 5B). The HD membrane
This comparative study was not done in the subgroup materials used were polysulfone (N  10) and cellulose
triacetate (N  4). There were no significant differencesof pre-dialysis patients because of the small number of
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Table 1. Subject profiles
Pre-dialyzed patients HD patients CAPD patients Controls
Number 20 46 23 29
Age years 54.810.1 57.912.3 50.88.31a 52.35.19
Dialysis duration years — 12.36.7 5.83.2a —
rHuEPO recipients/non-recipients 2/18 30/16 13/10 —
Hematocrit % 31.93.8 32.17.2 31.86.6 44.15.3
Platelet counts  109/L 225.360.1 196.275.4 214.861.0 232.651.3
Serum albumin g/dL 3.50.73 3.41.8 3.11.7 4.30.8
Serum urea nitrogen mg/dL 53.48.89a 80.211.1 56.610.2a 17.31.81
Serum creatinine mg/dL 6.24.8a 10.32.8 11.13.8 1.10.1
Data are expressed as mean  SD. Abbreviations are: HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; rhuEPO, recombinant human
erythropoietin.
a P  0.05 versus HD patients
Table 2. Effects of internal arteriovenous (AV) fistula
on platelet-derived microparticles (PMP) counts
Parameters AV fistula side Non-AV fistula side
PMP counts (N  10) 213.880.6 205.588.56
Data are expressed as mean  SD.
ence in the PMP counts between the blood samples from
the arms with and without AV fistula (Table 2).
DISCUSSION
The major findings of this study are (1) the PMP counts
were significantly elevated in a resting state in uremic
patients such as pre-dialyzed, HD, and CAPD patients,
compared with the age-matched healthy subjects, the
PMP counts were not significantly different among three
types of uremic groups; (2) the HD procedure and exis-
tence of internal AV fistula did not affect the PMP
counts, but rHuEPO treatment was possibly involved in
Fig. 5. (A) Time course changes of PMP counts in circulation during the further increase of PMP release; and (3) the PMPfour-hour HD treatments. PMPs were measured before HD, and 10
counts in the uremic patients who had experiencedminutes, 30 minutes, 2 hours, 3 hours, and 4 hours after the HD treat-
ment. Blood samples were collected from the artery-side port of circuit thrombotic events were much higher than those in the
tube before HD column. The PMP counts did not significantly change patients without such events. This result indicates thatduring HD treatment. (B) Changes in the PMP counts before and
an extreme increase of PMP counts may be responsibleafter HD column of different membrane materials. PMP counts were
specially measured before and after the HD column at 2 hours after for a high incidence of thrombosis in uremic patients.
HD treatment started. No significance between them was observed.
However, the primary cause of PMP elevation in uremiaThese studies were performed in 14 HD patients who used polysulfone
(N  10) and cellulose triacetate (N  4) membrane materials. Data was not clarified in this study.
are expressed as mean  SE. Our data showed that the counts of PMP enriched
with procoagulant activity are elevated in non-diabetic
uremic patients, as compared with the controls, regard-
less of uremic stages or dialysis modality. Nomura et albetween the data of two types of membrane materials
previously showed that PMP counts were increased in(data not shown).
uremic patients [31, 32], which was likely to support our
Influence of internal AV fistula on PMP counts current results. However, their data were deficient in
several points. The profiles of their uremic subjects didThis examination was performed in 10 HD patients
not include the stage of uremia, modality of dialysis,with an internal AV fistula. Blood samples were obtained
ages, and complications (for example, diabetes mellitus).from upstream veins close to AV fistula and almost si-
Moreover, their data were based upon so-called crudemultaneously obtained from cubital veins of the opposite
arm without AV fistula. There was no significant differ- PMPs that might include a lot of debris and non-func-
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tioning PMPs, as we described in our Methods section. We propose that a uremic milieu itself may cause an
increase in circulating PMPs. High shear stress by a cone-In contrast, we clarified the patients’ characteristics and
identified vesicles with procoagulant activity as PMPs. plate viscounter, which is thought to be most involved
in the in vitro PMP formation, is analogous with clinicalWe believe that our current report is comprehensive and
elaborates on the clinical significance of PMPs in uremic levels of fluid shear stress that may occur in atheroscle-
rotic arteries [15–19]. It would be natural to think thatpatients.
Our study shows the biological relevance of elevated such physiological stress is easy to induce in uremic pa-
tients who commonly have hypertension and systemicPMP counts in uremia. PMPs provide competent sur-
faces for the assembly of coagulation factors and may arterio-atherosclerosis [8]. Alternatively, unknown ure-
mic substances that are accumulated despite or by repeti-interact with components of the vessel walls, contributing
to thrombus and atheroma formation [13, 14, 23–26]. tive dialysis treatment may additionally impact the pro-
cess of PMP formation from activated platelets.Although the clinical significance of circulating PMPs in
the pathogenesis of thrombotic diseases is not sufficiently In conclusion, the counts of circulating PMPs were
elevated in three types of uremic patients compared withacknowledged yet, recent clinical evidence indicates that
an increase of circulating PMP counts is involved in the the healthy controls. The primary cause of PMP eleva-
tion was not clarified, but rHuEPO treatment could beincidence of ischemic heart diseases and cerebral strokes
[20–22]. Our data show a positive link between PMP involved as an enhancer of PMP release. In a uremic
setting overlapped by unfavorable factors such as uremiccounts and thrombotic events in uremic patients, sug-
gesting that an increase of PMP release in the circulatory toxins, pro-inflammatory cytokines, hypertension, and
systemic atherosclerosis, an increase of PMPs may be asystem underlies the high incidence of thrombotic dis-
eases in uremic patients [7, 8]. Alternatively, PMP could potential trigger of acute thrombotic accidents, even un-
der circumstances where the hemostatic functions ofbe a new marker or predictor of clinical thrombosis in
uremia. platelets are impaired.
We expected that changes of PMP release might con-
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